Bristol Myers Squibb Presents Results from Phase 1 Breakfree-2 Study of Zolacabtagene Autoleucel (BMS-986353) in Patients with Highly Active Relapsing and Progressive Forms of Multiple Sclerosis at MSToronto 2026
· Financial Post
PRINCETON, N.J. -- Bristol Myers Squibb (NYSE: BMY) today announced disclosure of interim safety and efficacy results from the multiple sclerosis (MS) cohorts of the Phase 1, single-arm, dose-escalation Breakfree-2 study evaluating zolacabtagene autoleucel (zola-cel; BMS-986353), an investigational, autologous CD19-directed CAR T cell therapy, in patients with highly active relapsing MS (haRMS) and progressive forms of MS (PMS). The data are being presented today in an oral presentation (Abstract #1615) at MSToronto 2026, the 10th Joint ACTRIMS-ECTRIMS Meeting taking place in Toronto, Canada. Read More
Visit esporist.org for more information.